These guidelines are meant to be a resource for both patients and providers as they implement best practices with the aim of eliminating preventable morbidity and mortality to HDFN. This guideline development process integrated clinical expertise, ethical considerations, and patient perspectives into transparent guidelines informed by systematic literature reviews. The full methodology is detailed within the published manuscripts and accompanying supplementary materials.
Recommendations were finalized through a robust Delphi voting process with over 40 clinicians and affected patients to finalize protective, patient-centered recommendations.
The Allo Hope Foundation would like to thank the clinicians and patients who dedicated their time and expertise to this life-saving initiative, made possible by partners at the THOR Network Foundation and the University of Pittsburgh Trauma and Transfusion Medicine Research Center. Funding for this project generously provided by U.S. DOD Combat Casualty Care Research Program.
How to Use These Guidelines
- Select the guideline most relevant to your role or clinical setting.
- Clinician checklists are designed to support point-of-care decision-making and institutional implementation.
- Patient summaries provide context and practical considerations to support shared decision-making with your care team.
Trauma & Transfusion
Whole blood transfusion guidance in trauma, including post-exposure mitigation strategies such as RhIG use and antibody surveillance.
Maternal–Fetal Medicine
Prenatal evaluation, surveillance, and fetal intervention pathways for pregnancies at risk for or affected by HDFN.
Neonatal
Delivery planning and newborn management, including monitoring and treatment of anemia and hyperbilirubinemia.
